Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 107

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 107
---
), “ Plasma-Derived Therapies” replaced the previous category of “ PDT Immunology” and included all plasma-derived products including those previously categorized within “ Rare Diseases” (e. g., FEIBA, CINRYZE). “ Vaccines” was presented as a separate key business area (previously included in “ Others”), reflecting the strategic focus on our dengue vaccine, QDENGA.

If the new categories were applied, revenue from “ Rare Disease” would be JPY 688.4 billion for the fiscal year ended March 31, 2024 and JPY 639.8 billion for the fiscal year ended March 31, 2023, revenue from “ Plasma-Derived Therapies” would be JPY 903.7 billion for the fiscal year ended March 31, 2024 and JPY 765.4

Table of Contents

billion for the fiscal year ended March 31, 2023, revenue from “ Vaccines” would be JPY 50.4 billion for the fiscal year ended March 31, 2024 and JPY 78.7 billion for the fiscal year ended March 31, 2023, revenue from “ Others” would be JPY 315.7 billion for the fiscal year ended March 31, 2024 and JPY 372.7 billion for the fiscal year ended March 31, 2023.

Year-on-year change in revenue for this fiscal year in each of our main business areas was primarily attributable to the following products:

• GI. InGI, revenue was JPY 1,216.2 billion (JPY +121.7 billion and +11.1% AER, +4.7% CER).

Sales of ENTYVIO (for ulcerative colitis (“ UC”) and Crohn’s disease) were JPY 800.9 billion (JPY +98.2 billion and +14.0% AER, +6.6% CER). Sales in the U. S. were JPY 546.1 billion (JPY +54.2 billion and +11.0% AER). The increase was due to favorable foreign exchange rates and demand in the first line biologic inflammatory bowel disease (“ IBD”) population primarily in UC. Sales in Europe and Canada were JPY 195.8 billion (JPY +33.4 billion and +20.5% AER), supported by favorable foreign exchange rates and